摘要
目的根据各文献中乳腺癌患者数目的汇总,通过Meta分析的方法来描述中国患者Cerb B-2在乳腺癌中的表达规律,从而为乳腺癌的预后和治疗提供依据。方法收集过去10年中国内发表的有关Cerb B-2与乳腺癌的文献,对原始数据汇总后进行统计处理。结果 Cerb B-2阳性表达率的平均值为52.8%,95%的可信区间为46.2%～59.3%。Cerb B-2阳性的表达与组织学分级,临床分期,月经状况以及肿块大小有关,与患者年龄无关。Cer Bb-2与乳腺癌的其余诱发因素有很好的相关性,其中与ER、PR呈负相关,与P53的阳性表达呈正相关。此外,Cerb B-2的表达还影响淋巴结转移以及生存时间,可以作为乳腺癌预后的重要指标。结论 Cerb B-2作为生物学分子指标,在乳腺癌的发生、发展及预后过程中起到了重要的作用,是极为可靠的生物学指标。
Objective According to the data of patients with breast cancer in the literature summary, to describe the regulation of Cerb B-2 over-expression in breast cancer through Meta-analysis, so as to provide the basis for the prognosis and treatment of breast cancer. Methods Reviewed all the published studies of the recent 10 years regarding Cerb B-2 and breast cancer, and processed the data after the original data summary. Results The average of positive expression rate of the Cerb B-2 was 52.8%, and the 95% confidence interval was 46.2% ～ 59.3%. Positive expression of Cerb B-2 was related to histological grade, clinical stage, menstrual conditions and the tumor size, but had nothing to do with the age of the patients. Moreover, Cerb B-2 had great correlation with other remote causes of breast cancer. It had negative correlation with ER and PR, but was positively correlated with the positive expression of P53. In addition, the expression of Cerb B-2 also affected the lymph node metastasis and survival time, and therefore it could serve as an important index of the prognosis of breast cancer.Conclusion Cerb B-2 plays an important role in the process of the occurrence, development and prognosis of breast cancer as a molecular biology. It is a reliable biological indicator.
出处
《肿瘤药学》
CAS
2015年第1期64-73,共10页
Anti-Tumor Pharmacy
